Manufacturer
BOEHRINGER INGELHEIM PHARMA KG
Contents
Palivizumab
Indication
Passive immunisation of infants against lower respiratory tract infections
Instruction
Child: <2 yr 15 mg/kg mthly during the season of resp syncytial virus (RSV) risk. Subsequent doses should be given mthly until the end of the season. Undergone cardiac bypass surgery: 15 mg/kg as soon as stable post-op. Admin preferably in the anterolateral thigh; vol >1 mL should be given in divided doses.
Drug interaction
No information.
Malaysia
